A Phase 2 interventional study of Stereotactic Arrhythmia Radiotherapy in Ventricular Tachycardia and Arrythmia, Cardiac, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Tachycardia, Ventricular with a site in Netherlands — 10 open to participants now, 11 under way, none of them phase 3. Tachycardia, Ventricular · Netherlands.
Among the 34 studies in Tachycardia, Ventricular with a site in Netherlands, this one is the 17th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2023, is one of 5 in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 28th registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →10 of the 34 studies in Tachycardia, Ventricular with a site in Netherlands are open now. Recruiting first, the newest first:
Catharina Ziekenhuis Eindhoven · Sites in Netherlands
Ages 18+
AtaCor Medical, Inc. · Sites in Netherlands, United States
Ages 18+
Cardurion Pharmaceuticals, Inc. · Sites in Netherlands, United States, Canada and 3 more countries
Ages 18–99
Imricor Medical Systems · Sites in Netherlands, Germany
Ages 18+
Stereotaxis · Sites in Netherlands, Denmark, Lithuania and 1 more country
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 70 across 281 interventional studies indexed under Tachycardia, Ventricular.
Median enrollment 270 across the 19 interventional studies, 379 across the 15 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 34 have an industry lead sponsor. The 10 most frequent:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 533 studies on the registry; 182 are open to participants now.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) has 2 studies filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
5 of the studies in Tachycardia, Ventricular with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT06658899Cardurion Pharmaceuticals, Inc.A Phase 2 Study of CRD-4730 in CPVT | 2027-04 |
| NCT05543798Imricor Medical SystemsVT Ablation in the iCMR | 2027-07 |
| NCT05439031Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2 | 2027-07 |
| NCT07324031AtaCor Medical, Inc.Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 34 studies in Tachycardia, Ventricular with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ventricular tachycardia (VT) is a malignant cardiac arrhythmia subjecting our patients to a high risk of sudden death, increased morbidity and reduced quality of life. Unfortunately, failure of treatment is common and VT recurrences remain an important concern. In these patients, stereotactic arrhythmia radiotherapy appears to be an effective and safe treatment. The mechanism of action however remains unknown and should be elucidated.
The objective of this phase 2, single arm, monocenter, pre-post intervention study is to evaluate the efficacy and safety of stereotactic arrhythmia radiotherapy and obtain insights in the mechanism of action by evaluating electro-anatomical alterations of stereotactic arrhythmia radiotherapy in patients with therapy refractory ventricular tachycardia.
Ventricular tachycardia (VT) is a malignant cardiac arrhythmia leading to a sudden abolition of cardiac function directly followed by a shortage of oxygen supply to essential organs such as the brain and heart. For this reason, VT is a cardiac emergency and should be treated within seconds to minutes before irreversible and potentially fatal organ damage follows. Current treatment options are limited to anti-arrhythmic drugs, an implantable cardioverter defibrillator (ICD), and invasive catheter ablation. Unfortunately, invasive cardiac VT ablation has the lowest success rate and the highest complication rates among all arrhythmia ablations.
Since the first case series published by Cuculich et al. (2017) and the first prospective trial published by Robinson et al. (2019), stereotactic arrhythmia radiotherapy (STAR) has evolved as a new treatment modality for patients with ventricular tachycardia refractory to conventional therapies. Patients are treated with a single radiotherapy fraction of 25 Gy at the determined pro-arrhythmic cardiac region with the use of standard stereotactic radiotherapy techniques. Experience with STAR is steadily growing worldwide. In the systematic review by Van der Ree et al. (2020), a reduction of >85% in VT episodes with a simultaneously promising safety profile was shown.
The mechanism of action of STAR is not yet fully known and is yet to be elucidated. The pathophysiological mechanism of VT relies on re-entry due to zigzag conduction by the surviving myocardial fibers in previously damaged heart tissue. At first, it was hypothesized that inducing cell-death by ionizing radiation leads to dense transmural fibrosis. As mature myocardial fibrosis is not able to propagate electrical activation this may lead to the abolishment of the zigzag conduction herewith reducing the chance of re-entry and VT. Fibrosis maturation takes several weeks to months to complete. However, the anti-arrhythmic effects seem to occur earlier. In preclinical studies, early electrophysiological alterations were demonstrated (Zhang et al. 2021). The gap-junction protein connexion-43 (Cx43) and the voltage gated sodium channels were upregulated, leading to a supraphysiological state with increased conduction velocity. Since a slow conduction pathway is required for re-entry, this could explain the timing of the observed effect, although the exact mechanism of action remains to be elucidated.
In the STARNL-2 study we aim to confirm our STARNL-1 pilot (6 patients) efficacy and safety data in a larger cohort and obtain insights in the electro-anatomical alterations of stereotactic arrhythmia radiotherapy in patients with therapy refractory ventricular tachycardia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Recurrence of VT after
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo stereotactic arrhythmia radiotherapy and subsequent follow-up.
Radiation: Stereotactic Arrhythmia Radiotherapy
Single radiation treatment of 25 Gy with external beam radiation therapy to the pro-arrhythmic region as determined by the cardiologist-electrophysiologist and radiation-oncologist combined
Also known as: Cardiac Radioablation
Reduction in the number of treated VT episodes
The main efficacy measure is a reduction in the number of treated VT episodes by ≥50% at the end of follow-up of 1 year (including a blanking period of 3 months). Net follow-up is 9 months compared to 9 months before treatment.
Time frame: 18 months (excluding 3 months of blanking period)
Rate of treatment related serious adverse events (SAEs)
The main safety measure is defined by a ≤20% rate of treatment related serious adverse events (SAEs), determined as the number of treatment related serious adverse events per number of treatment related adverse events.
Time frame: 12 months
Reduction in the number of treated and non-treated VT episodes
Reduction in the number of treated and non-treated VT episodes by ≥70% at the end of follow-up compared to the year before treatment.
Time frame: 18 months (excluding 3 months of blanking period)
Reduction in anti-arrhythmic drugs
A reduction of the daily dose by ≥50% (amiodarone or mexiletine) at the end of follow-up compared to baseline.
Time frame: 12 months
Quality of Life improvement
Quality of life improvement of ≥25% in the categories health change and social functioning as measured by the SF-36 questionnaire at the end of follow-up compared to baseline.
Time frame: 12 months
Cardiac safety
\>25% relative decrease in left ventricular ejection fraction measured by echocardiography at end of follow-up as compared to baseline
Time frame: 12 months
Pulmonary safety
\>25% relative decrease in forced expiratory volume in 1 second (FEV1) measured by pulmonary functions tests at end of follow-up as compared to baseline.
Time frame: 12 months
Pulmonary safety
\>25% relative decrease in diffusing capacity (DLCO) measured by pulmonary functions tests at one year after treatment as compared to baseline
Time frame: 12 months
Plan to share: No
Started May 2023 (actual). Primary completion is estimated for Jul 2027, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →